Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | Director | August 10, 2026 | August 11, 2026 |
| Starling Oncology, Inc.TOI · Entity 5327 | Director | July 27, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date August 10, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-10 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 1,250 · Balance 1,250 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. Row 2 · 2026-08-10 · Exercise / conversion · Acquired 6,500 · Balance 7,750 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. Row 3 · 2026-08-10 · Sale · Disposed 1,450 · Balance 6,300 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.79 to $107.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-08-10 · Sale · Disposed 2,800 · Balance 3,500 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.84 to $108.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2026-08-10 · Sale · Disposed 1,800 · Balance 1,700 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.89 to $109.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Row 6 · 2026-08-10 · Sale · Disposed 1,000 · Balance 700 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.05 to $111.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Row 7 · 2026-08-10 · Sale · Disposed 700 · Balance 0 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.15 to $111.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.36 · Expires 2032-06-27 | Direct | 0 |
Reported balance
After 2026-08-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-10 · Exercise / conversion · Disposed 1,250 · Balance 0 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.20 · Expires 2033-09-10 | Direct | 0 |
Reported balance
After 2026-08-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-10 · Exercise / conversion · Disposed 6,500 · Balance 0 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.79 to $107.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.84 to $108.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.89 to $109.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.05 to $111.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.15 to $111.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Starling Oncology, Inc.
Report date July 27, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 332,535 |
Reported balance
After 2026-07-27 transaction · row 1
1 source rowRow 1 · 2026-07-27 · Grant · Acquired 41,165 · Balance 332,535 F1: Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOC Telemed, Inc.
Report date April 06, 2022 · Filed April 07, 2022
Section 16 reporting ended · disclosed 2022-04-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-04-06 transaction · row 1
1 source rowRow 1 · 2022-04-06 · Disposition to issuer · Disposed 58,387 · Balance 0 F1: On April 6, 2022, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 2, 2022, by and among SOC Telemed, Inc. (the "Issuer"), Spark Parent, Inc. ("Parent") and Spark Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent, each share of the Issuer's Class A Common Stock (other than certain excluded shares) outstanding as of immediately prior to the effective time of the Merger (the "Effective Time") was canceled and automatically converted into the right to receive an amount in cash equal to $3.00 (the "Merger Consideration"), without any interest thereon and subject to any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2022, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 2, 2022, by and among SOC Telemed, Inc. (the "Issuer"), Spark Parent, Inc. ("Parent") and Spark Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent, each share of the Issuer's Class A Common Stock (other than certain excluded shares) outstanding as of immediately prior to the effective time of the Merger (the "Effective Time") was canceled and automatically converted into the right to receive an amount in cash equal to $3.00 (the "Merger Consideration"), without any interest thereon and subject to any applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 11, 2026 21:15 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $11.20 | $0.00 |
DisclosureSEC source: 0001779934-26-000004 · ownership.xml · derivative · entry 9 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,500 shares Expires 2033-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:15 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $19.36 | $0.00 |
DisclosureSEC source: 0001779934-26-000004 · ownership.xml · derivative · entry 8 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2032-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:15 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 700 | $111.41 | $77,987.00 |
DisclosureSEC source: 0001779934-26-000004 · ownership.xml · nonDerivative · entry 7 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.15 to $111.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:15 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 1,000 | $110.64 | $110,640.00 |
DisclosureSEC source: 0001779934-26-000004 · ownership.xml · nonDerivative · entry 6 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 700 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.05 to $111.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:15 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 1,800 | $109.30 | $196,740.00 |
DisclosureSEC source: 0001779934-26-000004 · ownership.xml · nonDerivative · entry 5 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,700 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.89 to $109.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:15 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 2,800 | $108.38 | $303,464.00 |
DisclosureSEC source: 0001779934-26-000004 · ownership.xml · nonDerivative · entry 4 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,500 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.84 to $108.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:15 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 1,450 | $107.58 | $155,991.00 |
DisclosureSEC source: 0001779934-26-000004 · ownership.xml · nonDerivative · entry 3 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,300 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.79 to $107.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:15 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 6,500 | $11.20 | $72,800.00 |
DisclosureSEC source: 0001779934-26-000004 · ownership.xml · nonDerivative · entry 2 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:15 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 1,250 | $19.36 | $24,200.00 |
DisclosureSEC source: 0001779934-26-000004 · ownership.xml · nonDerivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 22:54 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 41,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-26-000991 · ownership.xml · nonDerivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,535 F1 · kind: Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 6,090 | $0.00 Strike: $89.63 | $0.00 |
DisclosureSEC source: 0001779934-26-000002 · ownership.xml · derivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,090 Underlying: Common Stock · 6,090 shares Expires 2036-05-21 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:26 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 40,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001553350-25-000148 · ownership.xml · nonDerivative · entry 2 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,370 F2 · shares: . Represents restricted stock units that were fully vested upon grant. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:26 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 67,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001553350-25-000148 · ownership.xml · nonDerivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,247 F1 · shares: Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date. Read SEC document |
| May 22, 2025 Filed May 22, 2025 20:41 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.36 | $0.00 |
DisclosureSEC source: 0000950170-25-076406 · ownership.xml · derivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 21:28 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 56,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001799191-24-000057 · wk-form4_1732570125.xml · nonDerivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,346 F1 · shares: Represents restricted stock units that vest in full on TOI, Inc.'s 2025 annual shareholder meeting date, subject to continued service with the Company through such vesting date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 23:58 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0000950170-24-065541 · ownership.xml · derivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 22:06 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 56,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-042818 · wk-form4_1703801197.xml · nonDerivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,346 F1 · price: Represents restricted stock units that vest in full on TOI, Inc. 2024 annual shareholder meeting date, subject to continued service with the Company through such vesting date. Read SEC document |
| September 11, 2023 Filed Sep 14, 2023 01:14 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $11.20 | $0.00 |
DisclosureSEC source: 0000899243-23-018863 · doc4.xml · derivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2033-09-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 00:47 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 26,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-008828 · wf-form4_167944604001492.xml · nonDerivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,346 F1 · shares: Represents restricted stock units that vest in full on March 16, 2024, subject to continued service with the Company through such vesting date. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 22:33 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 22,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001799191-22-000036 · edgardoc.xml · nonDerivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,099 F1 · price: Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 22:33 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0000899243-22-024669 · doc4.xml · derivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 06, 2022 Filed Apr 7, 2022 20:26 UTC | SOC Telemed, Inc. TLMD · Entity 128175 | Disposition to issuerClass A Common Stock | 58,387 | $3.00 | $175,161.00 |
DisclosureSEC source: 0001209191-22-023675 · doc4.xml · nonDerivative · entry 1 McGeorge Anne · CIK 0001779934 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 6, 2022, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 2, 2022, by and among SOC Telemed, Inc. (the "Issuer"), Spark Parent, Inc. ("Parent") and Spark Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent, each share of the Issuer's Class A Common Stock (other than certain excluded shares) outstanding as of immediately prior to the effective time of the Merger (the "Effective Time") was canceled and automatically converted into the right to receive an amount in cash equal to $3.00 (the "Merger Consideration"), without any interest thereon and subject to any applicable withholding taxes. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:34 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 6,397 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-007093 · wf-form4_164807843000079.xml · nonDerivative · entry 2 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,391 Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:34 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 15,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-007093 · wf-form4_164807843000079.xml · nonDerivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,994 F1 · shares: Represents restricted stock units that vest in full on November 12, 2022, subject to continued service with the Company through such vesting date. F1 · price: Represents restricted stock units that vest in full on November 12, 2022, subject to continued service with the Company through such vesting date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:07 UTC | SOC Telemed, Inc. TLMD · Entity 128175 | GrantClass A Common Stock | 21,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038698 · doc4.xml · nonDerivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,387 F1 · shares: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's Class A Common Stock. The RSUs will vest in full on the first to occur of (x) the one-year anniversary of the grant date and (y) the date of the Issuer's next annual meeting of stockholders, subject to the continuous service of the Reporting Person as a member of the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:36 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $12.91 | $0.00 |
DisclosureSEC source: 0000899243-21-021849 · doc4.xml · derivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 18:36 UTC | SOC Telemed, Inc. TLMD · Entity 128175 | GrantClass A Common Stock | 37,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002458 · doc4.xml · nonDerivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,320 F1 · shares: Represents restricted stock units, each of which represents a contingent right to receive one share of the Issuer's Class A Common Stock, of which 1/3rd will vest on January 5 of each of 2022, 2023 and 2024, respectively, subject to the continuous service of the Reporting Person on each vesting date. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:25 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $9.99 | $0.00 |
DisclosureSEC source: 0000899243-20-015797 · doc4.xml · derivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 21:04 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 36,377 | $0.00 Strike: $14.94 | $0.00 |
DisclosureSEC source: 0000899243-19-017955 · doc4.xml · derivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,377 Underlying: Common Stock · 36,377 shares Expires 2029-06-19 F1 · derivative.exercise_date: This option shall vest and become exercisable over three years, with 33% of this option vesting on June 20, 2020, and the remainder vesting in 24 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.